Home › Funds › SCHOLTZ & COMPANY, LLC › APYX
SCHOLTZ & COMPANY, LLC position in APYX
APYX MEDICAL CORPORATION · Health Care
SCHOLTZ & COMPANY, LLC reported holding 10,000 shares of APYX (APYX MEDICAL CORPORATION) in its Q3 2026 13F filing — a position valued at US$24K, representing 0.01% of its reported portfolio and ranking #44 among its reported holdings. SCHOLTZ & COMPANY, LLC has disclosed APYX holdings in 12 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How SCHOLTZ & COMPANY, LLC's APYX position evolved
SCHOLTZ & COMPANY, LLC first disclosed a stake in APYX in Q3 2023 at 20,000 shares (US$64K). The position peaked in Q4 2025 at 20,000 shares, worth US$70K. Across 12 filings, SCHOLTZ & COMPANY, LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 9 time(s). The most recent filing (Q3 2026) shows 10,000 shares valued at US$24K. Notable position changes include a 50% trim in Q1 2026 (shares rose 22% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 20.00K | $64.00K | New |
| Q4 2023 | 20.00K | $52.00K | Hold |
| Q1 2024 | 20.00K | $27.20K | Hold |
| Q2 2024 | 20.00K | $26.80K | Hold |
| Q3 2024 | 20.00K | $24.80K | Hold |
| Q1 2025 | 20.00K | $27.40K | New |
| Q2 2025 | 20.00K | $45.00K | Hold |
| Q3 2025 | 20.00K | $42.80K | Hold |
| Q4 2025 | 20.00K | $70.00K | Hold |
| Q1 2026 | 10.00K | $36.90K | Reduce |
| Q2 2026 | 10.00K | $44.90K | Hold |
| Q3 2026 | 10.00K | $24.50K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About APYX and 13F data
APYX (APYX MEDICAL CORPORATION) is a Health Care company. 31 other funds we track also report a position in APYX — the largest reported positions include Nantahala Capital Management, LLC (US$14.7M), Archon Capital Management LLC (US$11.9M), Kanen Wealth Management LLC (US$3.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding APYX
- Nantahala Capital Management, LLC 3.27M sh · $14.68M · Q2 2026
- Archon Capital Management LLC 2.64M sh · $11.87M · Q2 2026
- Kanen Wealth Management LLC 1.55M sh · $3.82M · Q3 2026
- AIGH Capital Management LLC 1.13M sh · $2.76M · Q3 2026
- Silverberg Bernstein Capital Management LLC 1.02M sh · $2.50M · Q3 2026
More on SCHOLTZ & COMPANY, LLC
FAQ
How long has SCHOLTZ & COMPANY, LLC held APYX?
SCHOLTZ & COMPANY, LLC has disclosed APYX holdings in 12 of the last 13 reported quarters, going back to Q3 2023.
What is SCHOLTZ & COMPANY, LLC's current position in APYX?
As of Q3 2026, SCHOLTZ & COMPANY, LLC holds 10.00K shares of APYX (APYX MEDICAL CORPORATION), valued at $24.50K, representing 0.01% of its reported portfolio and ranking #44.
Has SCHOLTZ & COMPANY, LLC been buying or selling APYX?
In the latest 13F filing (Q3 2026), SCHOLTZ & COMPANY, LLC held unchanged its position in APYX. The position peaked in Q4 2025 at 20.00K shares.
Which other funds hold APYX?
Other major institutional holders of APYX include Nantahala Capital Management, LLC, Archon Capital Management LLC, Kanen Wealth Management LLC, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.